Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: Patient-reported outcomes from the CanCOLD cohort

Annals of Family Medicine

Volumn 13, Issue 1, 2015, Pages 41-48

  Van Dijk, Wouter ^a,b   Tan, Wan ^c   Li, Pei ^b   Guo, Best ^c   Li, Summer ^c   Benedetti, Andrea ^b   Bourbeau, Jean ^b   Aaron, Shawn ^d   Chapman, Kenneth ^d   Fitzgerald, Mark J ^d   Goldstein, Roger ^d   Hernandez, Paul ^d   Maltais, François ^d   Marciniuk, Darcy ^d   O’Donnell, Dennis ^d   Sin, Donald ^d   Cowie, Robert ^d   Coxson, Harvey ^d   Leipsic, Jonathon ^d   Hague, Cameron ^d   Road, Jeremy ^d   Atherton, Juli ^d   Baglole, Carolyn ^d   Daskalopoulou, Styliani ^d   Pierre Despres J ^d   Gershon, Andrea ^d   Lavoie, Kim ^d   Miedinger, David ^d   Rabasa, Remi ^d   Wilchesky, Machelle ^d   Andersen, Ross ^d   Doucet, Marie Eve ^d   Evans, Jessica ^d   Marra, Carlo ^d   Kimoff, John ^d   Pare, Peter ^d   Hogg, James C ^d   Perrault, Hélène ^d   Shatenstein, Bryna ^d   Shell, Bill ^d   Taivassalo, Tanja ^d   To, Teresa ^d   Jabet, Carole ^d   Sedeno, Maria ^d   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d NONE

Author keywords

Clinical relevance; COPD; Diagnosis; FEV1; Fixed ratio; Lower limit of normal; Lung diseases; Spirometry

Indexed keywords

ADULT; AGED; CANADA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMPLICATION; CROSS-SECTIONAL STUDY; DAILY LIFE ACTIVITY; DISEASE COURSE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPIROMETRY; VERY ELDERLY; VITAL CAPACITY;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; CANADA; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPIROMETRY; VITAL CAPACITY;

EID: 84920971189     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.1714     Document Type: Article

References (28)

1. Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for diagnosis, management, and prevention of COPD. http://www.goldcopd.org/uploads/users/fles/GOLD_Report_2014_ Jun11.pdf. Updated Jan 2014. Accessed July 1, 2014.
2. Schirnhofer L, Lamprecht B, Vollmer WM, et al. COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest. 2007;131(1):29-36.
3. Soriano JB, Miravitlles M, Borderías L, et al. Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors [in Spanish]. Arch Bronconeumol. 2010;46(10):522-530.
4. Waked M, Khayat G, Salameh P. Chronic obstructive pulmonary disease prevalence in Lebanon: a cross-sectional descriptive study. Clin Epidemiol. 2011; 3: 315-323.
5. Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagno-sis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010;182(7):673-678.
6. Han MK, Kim MG, Mardon R, et al. Spirometry utilization for COPD: how do we measure up? Chest. 2007;132(2):403-409.
7. Vanfeteren LE, Franssen FM, Wesseling G, Wouters EF. The prevalence of chronic obstructive pulmonary disease in Maastricht, the Netherlands. Respir Med. 2012;106(6):871-874.
8. Joo MJ, Au DH, Fitzgibbon ML, McKell J, Lee TA. Determinants of spirometry use and accuracy of COPD diagnosis in primary care. J Gen Intern Med. 2011; 26 (11):1272-1277.
9. Güder G, Brenner S, Angermann CE, et al. “GOLD or lower limit of normal defnition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort s tu dy.” Respir Res. 2012;13 (1):13.
10. Fromer L. Diagnosing and treating COPD: understanding the challenges and fnding solutions. Int J Gen Med. 2011; 4: 729-739.
11. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.
12. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care partial update. http://www.nice.org.uk/guidance/CG101. Published Jun 2010. Accessed July 1, 2014.
13. Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassifcation of airway obstruction. Thorax. 2008;63(12):1046-1051.
14. Quanjer PH, Furberg CD. GOLD COPD stage I is not associated with increased risk of death. Respir Med. 2012;106(1):153.
15. Quanjer PH, Enright PL, Miller MR, et al. The need to change the method for defining mild airway obstruction. Eur Respir J. 2011; 37(3):720-722.
16. Enright PL, Kaminsky DA. Strategies for screening for chronic obstructive pulmonary disease. Respir Care. 2003;48(12):1194-1201, discussion 1201-1203.
17. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968.
18. Vanfeteren LE, Franssen FM, Wesseling G, Wouters EF. The prevalence of chronic obstructive pulmonary disease in Maastricht, the Netherlands. Respir Med. 2012;106(6):871-874.
19. Mohamed Hoesein FA, Zanen P, Lammers JW. Lower limit of normal or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review. Respir Med. 2011;105(6):907-915.
20. van Dijk WD, Gupta N, Tan WC, Bourbeau J. Clinical relevance of diagnosing COPD by fixed ratio or lower limit of normal: a systematic review. COPD. 2014:11(1):113-120.
21. Tan WC, Bourbeau J, FitzGerald JM, et al. Can age and sex explain the variation in COPD rates across large urban cities? A population study in Canada. Int J Tuberc Lung Dis. 2011;15(12):1691-1698.
22. Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
23. Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest. 2010;137(1):138-145.
24. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008;63(9):768-774.
25. Enright PL. GOLD stage I is not a COPD risk factor. Thorax. 2007; 62(12):1107, author reply 1108-1109.
26. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975-981.
27. Mannino DM, Diaz-Guzman E. Interpreting lung function data using 80% predicted and fixed thresholds identifies patients at increased risk of mortality. Chest. 2012;141(1):73-80.
28. Mannino DM, Sonia Buist A, Vollmer WM. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax. 2007;62(3):237-241.